104 related articles for article (PubMed ID: 8009568)
1. Determination of fostriecin pharmacokinetics in plasma using high-pressure liquid chromatography assay.
Pillon L; Moore MJ; Thiessen JJ
Ther Drug Monit; 1994 Apr; 16(2):186-90. PubMed ID: 8009568
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin.
de Jong RS; Mulder NH; Uges DR; Sleijfer DT; Höppener FJ; Groen HJ; Willemse PH; van der Graaf WT; de Vries EG
Br J Cancer; 1999 Feb; 79(5-6):882-7. PubMed ID: 10070885
[TBL] [Abstract][Full Text] [Related]
3. Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.
de Jong S; Zijlstra JG; Mulder NH; de Vries EG
Cancer Chemother Pharmacol; 1991; 28(6):461-4. PubMed ID: 1657425
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of fostriecin given as an intravenous bolus daily for five consecutive days.
Lê LH; Erlichman C; Pillon L; Thiessen JJ; Day A; Wainman N; Eisenhauer EA; Moore MJ
Invest New Drugs; 2004 Apr; 22(2):159-67. PubMed ID: 14739664
[TBL] [Abstract][Full Text] [Related]
5. Fostriecin: a review of the preclinical data.
de Jong RS; de Vries EG; Mulder NH
Anticancer Drugs; 1997 Jun; 8(5):413-8. PubMed ID: 9215602
[TBL] [Abstract][Full Text] [Related]
6. Total synthesis of fostriecin (CI-920).
Boger DL; Ichikawa S; Zhong W
J Am Chem Soc; 2001 May; 123(18):4161-7. PubMed ID: 11457179
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of type II topoisomerase by fostriecin.
Boritzki TJ; Wolfard TS; Besserer JA; Jackson RC; Fry DW
Biochem Pharmacol; 1988 Nov; 37(21):4063-8. PubMed ID: 2847752
[TBL] [Abstract][Full Text] [Related]
8. Renal toxicity of the anticancer drug fostriecin.
de Jong RS; de Vries EG; Meijer S; de Jong PE; Mulder NH
Cancer Chemother Pharmacol; 1998; 42(2):160-4. PubMed ID: 9654117
[TBL] [Abstract][Full Text] [Related]
9. Versatile enantiocontrolled synthesis of (+)-fostriecin.
Esumi T; Okamoto N; Hatakeyama S
Chem Commun (Camb); 2002 Dec; (24):3042-3. PubMed ID: 12536807
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assay.
Scheithauer W; Von Hoff DD; Clark GM; Shillis JL; Elslager EF
Eur J Cancer Clin Oncol; 1986 Aug; 22(8):921-6. PubMed ID: 3770049
[TBL] [Abstract][Full Text] [Related]
11. Determination and pharmacokinetic study of indirubin in rat plasma by high-performance liquid chromatography.
Deng XY; Zheng SN; Gao GH; Fan G; Li F
Phytomedicine; 2008 Apr; 15(4):277-83. PubMed ID: 18337073
[TBL] [Abstract][Full Text] [Related]
12. The antitumor drug fostriecin induces vimentin hyperphosphorylation and intermediate filament reorganization.
Ho DT; Roberge M
Carcinogenesis; 1996 May; 17(5):967-72. PubMed ID: 8640945
[TBL] [Abstract][Full Text] [Related]
13. Assay for the quinocarmycin analog DX-52-1 in human plasma using high-performance liquid chromatography with automated column switching and low wavelength ultraviolet detection.
Supko JG; Soglia JR; Nair RV
J Chromatogr B Biomed Sci Appl; 1998 Sep; 714(2):341-53. PubMed ID: 9766875
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
[TBL] [Abstract][Full Text] [Related]
15. Total synthesis of fostriecin (CI-920) via a convergent route.
Miyashita K; Ikejiri M; Kawasaki H; Maemura S; Imanishi T
Chem Commun (Camb); 2002 Apr; (7):742-3. PubMed ID: 12119701
[TBL] [Abstract][Full Text] [Related]
16. High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma.
Kim HK; Lin CC; Parker D; Veals J; Lim J; Likhari P; Statkevich P; Marco A; Nomeir AA
J Chromatogr B Biomed Sci Appl; 1997 Dec; 703(1-2):225-33. PubMed ID: 9448080
[TBL] [Abstract][Full Text] [Related]
17. Determination of the antitumor agent depsipeptide in plasma by liquid chromatography on serial octadecyl stationary phases.
Chassaing C; Marshall JL; Wainer IW
J Chromatogr B Biomed Sci Appl; 1998 Nov; 719(1-2):169-76. PubMed ID: 9869377
[TBL] [Abstract][Full Text] [Related]
18. Preclinical toxicological evaluation of fostriecin, a novel anticancer antibiotic, in rats.
Susick RL; Hawkins KL; Pegg DG
Fundam Appl Toxicol; 1990 Aug; 15(2):258-69. PubMed ID: 2227154
[TBL] [Abstract][Full Text] [Related]
19. Determination of idarubicin and idarubicinol in rat plasma using reversed-phase high-performance liquid chromatography and fluorescence detection.
Kuhlmann O; Hofmann S; Weiss M
J Chromatogr B Biomed Sci Appl; 1999 May; 728(2):279-82. PubMed ID: 10406213
[TBL] [Abstract][Full Text] [Related]
20. Comparison of effects of fostriecin, novobiocin, and camptothecin, inhibitors of DNA topoisomerases, on DNA replication and repair in human cells.
Gedik CM; Collins AR
Nucleic Acids Res; 1990 Feb; 18(4):1007-13. PubMed ID: 2156221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
